S&P 500   3,854.21 (+0.06%)
DOW   31,195.02 (+0.02%)
QQQ   325.83 (+0.64%)
AAPL   136.15 (+3.12%)
MSFT   225.93 (+0.71%)
FB   272.50 (+1.88%)
GOOGL   1,888.52 (+0.45%)
AMZN   3,317.85 (+1.67%)
TSLA   847.40 (-0.36%)
NVDA   544.76 (+1.89%)
BABA   259.39 (-2.30%)
CGC   33.90 (+0.80%)
GE   11.12 (-2.37%)
MU   83.48 (-0.02%)
AMD   90.61 (+2.10%)
NIO   57.88 (+0.29%)
T   28.91 (-0.17%)
F   11.67 (+7.46%)
ACB   11.16 (-3.29%)
BA   207.17 (-2.02%)
DIS   172.36 (-0.74%)
NFLX   572.64 (-2.34%)
GILD   67.04 (-1.40%)
S&P 500   3,854.21 (+0.06%)
DOW   31,195.02 (+0.02%)
QQQ   325.83 (+0.64%)
AAPL   136.15 (+3.12%)
MSFT   225.93 (+0.71%)
FB   272.50 (+1.88%)
GOOGL   1,888.52 (+0.45%)
AMZN   3,317.85 (+1.67%)
TSLA   847.40 (-0.36%)
NVDA   544.76 (+1.89%)
BABA   259.39 (-2.30%)
CGC   33.90 (+0.80%)
GE   11.12 (-2.37%)
MU   83.48 (-0.02%)
AMD   90.61 (+2.10%)
NIO   57.88 (+0.29%)
T   28.91 (-0.17%)
F   11.67 (+7.46%)
ACB   11.16 (-3.29%)
BA   207.17 (-2.02%)
DIS   172.36 (-0.74%)
NFLX   572.64 (-2.34%)
GILD   67.04 (-1.40%)
S&P 500   3,854.21 (+0.06%)
DOW   31,195.02 (+0.02%)
QQQ   325.83 (+0.64%)
AAPL   136.15 (+3.12%)
MSFT   225.93 (+0.71%)
FB   272.50 (+1.88%)
GOOGL   1,888.52 (+0.45%)
AMZN   3,317.85 (+1.67%)
TSLA   847.40 (-0.36%)
NVDA   544.76 (+1.89%)
BABA   259.39 (-2.30%)
CGC   33.90 (+0.80%)
GE   11.12 (-2.37%)
MU   83.48 (-0.02%)
AMD   90.61 (+2.10%)
NIO   57.88 (+0.29%)
T   28.91 (-0.17%)
F   11.67 (+7.46%)
ACB   11.16 (-3.29%)
BA   207.17 (-2.02%)
DIS   172.36 (-0.74%)
NFLX   572.64 (-2.34%)
GILD   67.04 (-1.40%)
S&P 500   3,854.21 (+0.06%)
DOW   31,195.02 (+0.02%)
QQQ   325.83 (+0.64%)
AAPL   136.15 (+3.12%)
MSFT   225.93 (+0.71%)
FB   272.50 (+1.88%)
GOOGL   1,888.52 (+0.45%)
AMZN   3,317.85 (+1.67%)
TSLA   847.40 (-0.36%)
NVDA   544.76 (+1.89%)
BABA   259.39 (-2.30%)
CGC   33.90 (+0.80%)
GE   11.12 (-2.37%)
MU   83.48 (-0.02%)
AMD   90.61 (+2.10%)
NIO   57.88 (+0.29%)
T   28.91 (-0.17%)
F   11.67 (+7.46%)
ACB   11.16 (-3.29%)
BA   207.17 (-2.02%)
DIS   172.36 (-0.74%)
NFLX   572.64 (-2.34%)
GILD   67.04 (-1.40%)
Log in
NASDAQ:HRTX

Heron Therapeutics Stock Forecast, Price & News

$17.57
-0.02 (-0.11 %)
(As of 01/21/2021 01:32 PM ET)
Add
Compare
Today's Range
$17.43
Now: $17.57
$17.98
50-Day Range
$17.11
MA: $19.10
$22.14
52-Week Range
$9.60
Now: $17.57
$24.76
Volume18,316 shs
Average Volume952,621 shs
Market Capitalization$1.60 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.52
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron) extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing HTX-011, an investigational, dual-acting, and fixed-dose combination of the local anesthetic bupivacaine with a low dose of the nonsteroidal anti-inflammatory drug meloxicam that is in Phase III clinical trial for pain management; and HTX-034, a product candidate for postoperative pain management. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.
Heron Therapeutics logo

MarketRank

Overall MarketRank

1.68 out of 5 stars

Medical Sector

226th out of 1,926 stocks

Pharmaceutical Preparations Industry

112th out of 773 stocks

Analyst Opinion: 3.4Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:HRTX
CUSIPN/A
Phone858-251-4400
Employees231

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$145.97 million
Book Value$4.48 per share

Profitability

Net Income$-204,750,000.00
Net Margins-216.18%

Miscellaneous

Market Cap$1.60 billion
Next Earnings Date3/1/2021 (Estimated)
OptionableOptionable
$17.57
-0.02 (-0.11 %)
(As of 01/21/2021 01:32 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive HRTX News and Ratings via Email

Sign-up to receive the latest news and ratings for HRTX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Heron Therapeutics (NASDAQ:HRTX) Frequently Asked Questions

How has Heron Therapeutics' stock been impacted by Coronavirus (COVID-19)?

Heron Therapeutics' stock was trading at $13.64 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, HRTX stock has increased by 29.2% and is now trading at $17.62.
View which stocks have been most impacted by COVID-19
.

Is Heron Therapeutics a buy right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Heron Therapeutics in the last year. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Heron Therapeutics stock.
View analyst ratings for Heron Therapeutics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Heron Therapeutics?

Wall Street analysts have given Heron Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Heron Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as Heron Therapeutics' CEO?

1,428 employees have rated Heron Therapeutics CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 59% among Heron Therapeutics' employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is Heron Therapeutics' next earnings date?

Heron Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, March 1st 2021.
View our earnings forecast for Heron Therapeutics
.

How were Heron Therapeutics' earnings last quarter?

Heron Therapeutics, Inc. (NASDAQ:HRTX) released its quarterly earnings data on Thursday, November, 5th. The biotechnology company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.63) by $0.01. The biotechnology company had revenue of $19.97 million for the quarter, compared to analysts' expectations of $18 million. Heron Therapeutics had a negative net margin of 216.18% and a negative return on equity of 65.06%.
View Heron Therapeutics' earnings history
.

What price target have analysts set for HRTX?

7 equities research analysts have issued twelve-month target prices for Heron Therapeutics' shares. Their forecasts range from $21.00 to $44.00. On average, they anticipate Heron Therapeutics' share price to reach $31.50 in the next twelve months. This suggests a possible upside of 78.8% from the stock's current price.
View analysts' price targets for Heron Therapeutics
or view Wall Street analyst' top-rated stocks.

Who are some of Heron Therapeutics' key competitors?

What other stocks do shareholders of Heron Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Heron Therapeutics investors own include Micron Technology (MU), Pfizer (PFE), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), NVIDIA (NVDA), Editas Medicine (EDIT), Immunomedics (IMMU), bluebird bio (BLUE), AT&T (T) and Amarin (AMRN).

Who are Heron Therapeutics' key executives?

Heron Therapeutics' management team includes the following people:
  • Dr. Barry D. Quart, Chairman & CEO (Age 63, Pay $954.11k)
  • Mr. John W. Poyhonen, Pres & Chief Commercial Officer (Age 60, Pay $421.25k)
  • Ms. Kimberly J. Manhard, Exec. VP of Drug Devel. & Director (Age 60, Pay $694.59k)
  • Mr. David L. Szekeres, Exec. VP & COO (Age 46)
  • Ms. Lisa Peraza, VP & Chief Accounting Officer (Age 44)
  • Mr. Sean T. Ristine, VP of HR (Age 50)
  • Dr. Thomas B. Ottoboni, Chief Scientific Officer and Sr. VP of Pharmaceutical & Translational Sciences (Age 61)
  • Mr. Michael E. Mathews, Sr. VP of Pain Franchise (Age 57)
  • Dr. Chris M. Storgard, Chief Medical Officer (Age 54)

What is Heron Therapeutics' stock symbol?

Heron Therapeutics trades on the NASDAQ under the ticker symbol "HRTX."

Who are Heron Therapeutics' major shareholders?

Heron Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Private Asset Management Inc. (0.19%) and Pacer Advisors Inc. (0.01%). Company insiders that own Heron Therapeutics stock include Barry D Quart, David Leslie Szekeres, John Poyhonen, Kevin C Tang, Kimberly Manhard and Waage Christian.
View institutional ownership trends for Heron Therapeutics
.

Which major investors are selling Heron Therapeutics stock?

HRTX stock was sold by a variety of institutional investors in the last quarter, including Private Asset Management Inc.. Company insiders that have sold Heron Therapeutics company stock in the last year include David Leslie Szekeres, and Kimberly Manhard.
View insider buying and selling activity for Heron Therapeutics
or view top insider-selling stocks.

Which major investors are buying Heron Therapeutics stock?

HRTX stock was acquired by a variety of institutional investors in the last quarter, including Pacer Advisors Inc.. Company insiders that have bought Heron Therapeutics stock in the last two years include Barry D Quart, John Poyhonen, Kevin C Tang, and Waage Christian.
View insider buying and selling activity for Heron Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Heron Therapeutics?

Shares of HRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Heron Therapeutics' stock price today?

One share of HRTX stock can currently be purchased for approximately $17.62.

How big of a company is Heron Therapeutics?

Heron Therapeutics has a market capitalization of $1.60 billion and generates $145.97 million in revenue each year. The biotechnology company earns $-204,750,000.00 in net income (profit) each year or ($2.50) on an earnings per share basis. Heron Therapeutics employs 231 workers across the globe.

What is Heron Therapeutics' official website?

The official website for Heron Therapeutics is www.herontx.com.

How can I contact Heron Therapeutics?

Heron Therapeutics' mailing address is 4242 CAMPUS POINT COURT SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-251-4400 or via email at [email protected]

This page was last updated on 1/21/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.